Physician profile
Allyson Walsh
NPI 1568821981
$4,785.05
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $872 · 2023: $2,366 · 2024: $1,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,322 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,321.97 |
| Education | $364.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,003.81 | 2023-2024 | Sotyktu |
| Incyte Corporation | $820.31 | 2022-2024 | Opzelura |
| Janssen Biotech, INC. | $815.33 | 2022-2024 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $772.85 | 2021-2024 | |
| Pfizer INC. | $311.27 | 2022-2024 | |
| Dermavant Sciences, INC. | $262.22 | 2024 | Vtama |
| Verrica Pharmaceuticals INC. | $212.77 | 2023-2024 | Ycanth |
| Leo Pharma INC. | $131.85 | 2022-2024 | Adbry |
| Genzyme Corporation | $107.60 | 2021-2023 | |
| Amgen INC. | $94.57 | 2022-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $52.11 | 2024 | Libtayo, Dupixent |
| Lilly USA, LLC | $47.72 | 2024 | Olumiant, Taltz |
| Organogenesis INC. | $41.16 | 2023 | Puraply |
| Paratek Pharmaceuticals, INC. | $36.98 | 2022-2023 | Nuzyra |
| Fresenius Kabi USA, LLC | $25.19 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.98 | 2023 | |
| Ucb, INC. | $24.33 | 2023 | Cimzia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.